Funded Research

Enabling Applied Genomic Technologies in Pediatrics
Principal Investigator(s):
  • Sheila A. Stewart, Ph.D. Cell Biology and Physiology Visit Website
Status:
Completed
Center(s):
  • McDonnell Pediatric Cancer Center
Award Mechanism:
Core Large Initiative
Project Period:
7/1/2007 - 6/30/2010
Total Amount:
$600,000
Collaborators:
Elaine R. Mardis, David R. Piwnica-Worms

This project is developing technology that allows the selective manipulation of gene expression in human cancer cells derived directly from children with pediatric brain tumors. These efforts will permit deciphering of the signal transduction pathways critical for brain cancer cell growth and survival and allow the development of novel therapeutic approaches in affected children. Although such methods of discovery have been utilized in model organisms, similar approaches in human systems have not been feasible due to the inability to easily manipulate gene expression. The work in this initiative takes advantage of a newly defined system for manipulation of RNA expression termed RNAi, a discovery that was awarded the 2007 Nobel Prize in Physiology or Medicine. Although initial experiments will be focused on pediatric brain cancer (see Leonard, Rubin), it is apparent that once produced and made available to the community, this reagent will allow individual investigators to ask innovative biological questions relevant to gene function in primary cultures. This invaluable library is available to the entire Washington University community.

Project Update:

Final Report: In the original grant, this team proposed to generate transfection-quality DNA from the human shRNA library and facilitate its distribution and utilization across the University. In addition, they proposed to utilize some of the funds to develop technologies and feasibility screens for the use of this shRNA library. The team completed replication of the human shRNA library ahead of schedule, and has been supplying clones to the Washington University research community for $4/clone. This cost-effective fee is a direct result of Institute funding, and greatly benefits pediatric biomedical research. Recently, Dr. Stewart and her collaborators have received additional core funding from the Institute to continue these efforts. Dr. Stewart's laboratory remains at the forefront of RNAi technology, which is critical for many kinds of genetic research in children.